(Q46708234)

English

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

scientific article published on 29 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

0 references

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

author name string

Alan K Burnett

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Nigel H Russell

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Dominic Culligan

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Jamie Cavanagh

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Jonathan Kell

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Keith Wheatley

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Andra Virchis

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Donald Milligan

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

AML Working Group of the UK National Cancer Research Institute

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

language of work or name

0 references

publication date

29 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

158

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

519-522

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

Lipid posttranslational modifications. Farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Geranylgeranyltransferase I as a target for anti-cancer drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09165.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2012.09165.X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/22639959

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46708234&oldid=1513616042"